Navigation Links
Epilepsy Foundation To Present Epilepsy Therapy Project Lifetime Accelerator Award To Henrik Klitgaard, Ph.D., Recognizing Contributions To New Therapies
Date:4/30/2013

LANDOVER, Md., April 30, 2013 /PRNewswire-USNewswire/ -- The Epilepsy Foundation announced today that Henrik Klitgaard , Ph.D., Vice President and Fellow, Neurosciences Therapeutic Area, UCB, has been named the recipient of the Epilepsy Therapy Project Lifetime Accelerator Award in recognition of his commitment and contributions to the field of epilepsy and to the people affected by it.  Dr. Klitgaard will be honored at the Antiepileptic Drug and Device Trials (AED) XII Conference being held May 15-17, 2013, at the Turnberry Isle Miami Hotel, Aventura, FL. 

A leading and accomplished researcher in the epilepsy community, Dr. Klitgaard has conducted antiepileptic drug discovery in the pharmaceutical industry for more than two decades, most notably contributing to the discovery and development of levetiracetam.  Currently, he serves as Vice President and Fellow, Neurosciences Therapeutic Area, UCB, where he has contributed to the research and development of multiple promising new anti-epilepsy drug candidates including PPSI, seletracetam and brivaracetam. 

Dr. Klitgaard was selected for the honor by an independent committee of global thought leaders and clinical investigators in epilepsy therapy discovery and development.

"Dr. Klitgaard truly embodies the definition of the Lifetime Accelerator Award with his lifelong commitment to the epilepsy community and the advancement of important new therapies," said Jacqueline A. French , M.D., Director of the Epilepsy Study Consortium, and Director of Clinical Trials at NYU's Comprehensive Epilepsy Center.  "We are delighted to be able to recognize the significant contributions Dr. Klitgaard has made in drug development and to research in the field of epilepsy at the AED XII Conference."

"We're pleased to honor Dr. Klitgaard this year and to acknowledge both his notable contributions to important new therapies now available to patients and his creativity and leadership in setting new directions for the research agenda in epilepsy moving forward,"  said Warren Lammert , Co-founder of the Epilepsy Therapy Project. 

Dr. Klitgaard earned his Ph.D. in Human Physiology in 1989 at the August Krogh Institute, University of Copenhagen, Denmark. His postdoctoral work was conducted at different academic institutions, including the Pasteur Institute, Paris, France and the Harvard Medical School.  Dr. Klitgaard joined the pharmaceutical industry in 1990 at Novo Nordisk, where he established a platform for antiepileptic drug discovery.  He was recruited in 1994 to UCB as Head of CNS Research where he focused the drug discovery efforts on the search for new antiepileptic drugs.  Dr. Klitgaard was later appointed Vice President and remained Head of CNS Research until 2012 when he was nominated UCB Fellow.  He is the author of more than 80 peer-reviewed publications, as well as reviews and book chapters on both basic and applied aspects of epilepsy research and antiepileptic drug discovery and has contributed numerous lectures at epilepsy meetings.  Dr. Klitgaard serves as a scientific adviser to the patient organization C.U.R.E. (Citizens United for Research in Epilepsy) and is a member for the Anticonvulsant Screening Program at the National Institutes of Health (NIH).  

The Epilepsy Therapy Project Lifetime Accelerator Award was established to honor physicians, scientists, industry leaders and other individuals who have demonstrated a lifelong commitment to bringing new therapies to people living with epilepsy.  Harvey Kupferberg , Ph.D., past Chief of the Preclinical Pharmacology Section, Epilepsy Branch, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health was conferred the 2012 Accelerator Award.  

About Epilepsy
When a person has two or more unprovoked seizures, they have epilepsy, which affects nearly three million people in the United States and 65 million people worldwide.  This year, another 200,000 people in our country will be diagnosed with epilepsy.  Despite all available treatments, 30 to 40 percent of all people with epilepsy continue to experience uncontrolled seizures while many more experience less than optimal seizure control.   

About the AED XII Conference and the Second Annual Epilepsy Shark Tank Event
The Antiepileptic Drug and Device Trials (AED) XII Conference is being held May 15-17, 2013, at the Turnberry Isle Miami Hotel, Aventura, FL. The three-day conference will focus on issues related to antiepileptic drug development from preclinical discoveries through clinical evaluations with the final day devoted to showcasing the most promising epilepsy therapies in development.  The 2013 conference will also include the second annual Epilepsy Therapy Project Shark Tank Event which awards a grant to the best new idea in epilepsy treatment and care.  The "Shark Tank" finalists will present their concepts and product candidates at the conference; the winning entry will be selected by live voting by an expert panel of judges and audience members representing industry, patient advocacy, investment, research and medical communities.  The project deemed most innovative will be announced at the conclusion of the conference, and the winner will receive a $100,000 grant to help accelerate the idea from concept to people with epilepsy.

For more information or to register for the conference, please visit http://www.epilepsy.com/etp/aedtrialxii.

About the Epilepsy Therapy Project
The Epilepsy Therapy Project was founded in 2002 by a group of parents, distinguished physicians, and researchers to support the commercialization of new therapies through direct grants and investments in promising academic and commercial projects.  In December 2012, ETP merged with the Epilepsy Foundation and continues to support translational research and new product development as an initiative under the Epilepsy Foundation umbrella. 

About the Epilepsy Foundation
The Epilepsy Foundation, a national non-profit with affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation's goals are to ensure that people with seizures are able to participate in all life experiences; and to prevent, control and cure epilepsy through services, education, advocacy and research, so not another moment is lost to seizures.

To learn more about epilepsy, visit www.epilepsy.com.  'Like' the Epilepsy Foundation on Facebook at www.facebook.com/epilepsyfoundationofamerica and follow us on Twitter at www.twitter.com/epilepsyfdn

Media Contacts:
Karen L. Bergman , BCC Partners, (650) 575-1509; kbergman@bccpartners.com
Susan M. Pietropaolo , BCC Partners, (201) 923-2049; spietropaolo@bccpartners.com


'/>"/>
SOURCE Epilepsy Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Call for Entries: International Bureau for Epilepsy and UCB launch the 2012 Excellence in Epilepsy Journalism Award to recognize exceptional reporting on epilepsy
2. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
3. Elsevier Launches New Open Access Journal - Epilepsy & Behavior Case Reports
4. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
5. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
6. NeuroSigma Awarded Fast Track SBIR Grant by the NIH for Development of Implantable sTNS System for Drug Resistant Epilepsy
7. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
8. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
9. American Academy of Family Physicians Foundation Launches Cities for Life
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... , January 13, 2017 This ... see how they have fared at yesterday,s closing bell: ... Biopharma Inc. (NASDAQ: GALE ), and ACADIA ... harness cellular and biomolecular processes to develop technologies and ... environmental footprint, feed the hungry, use less and cleaner ...
(Date:1/13/2017)... 2017 The 2016 election resulted in ... states voting in favor of legalizing cannabis for recreational use, ... in the U.S. In addition, the state of ... cannabis products sales. The ArcView Group has published an updated ... cannabis sales in the U.S. last year reached $6.7 billion, a ...
(Date:1/13/2017)... 2017   JDRF , the leading global ... pleased to announce that after more than a ... & Medicaid Services (CMS) has recognized continuous glucose ... use in making diabetes treatment decisions as durable ... eligible for coverage under Medicare. JDRF has been ...
Breaking Medicine Technology:
(Date:1/16/2017)... New York (PRWEB) , ... January 16, 2017 ... ... SightMD today announced the addition of Victor Giamos, MD to their ... of SightMD and Managing Partner at North Shore Eye Care, a division of ...
(Date:1/16/2017)... , ... January 16, 2017 , ... ... availability of the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol ... protocols to understand the scope of their EHS regulatory obligations and rapidly collect, ...
(Date:1/16/2017)... ... ... St. Louisans are well-aware of the following facts at present:, ... be having no effect on keeping this particularly bad strain of the flu away , ... sneezing, or sniffling , These facts are well-known among the team at ...
(Date:1/16/2017)... Beverly Hills, CA (PRWEB) , ... January 16, ... ... published a manuscript in the Aesthetic Surgery Journal , the official journal ... study he conducted on lower eyelid retraction surgery. The procedure is designed to ...
(Date:1/16/2017)... ... January 16, 2017 , ... One thing common to all types ... to test for, as well. The money spent screening for and treating cancer in ... U.S. screen patients for cancer more than in any other country that has an ...
Breaking Medicine News(10 mins):